Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 83 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboardHealthcare sectorCompany signalsFiling ledgerData API
48/100

Balanced insider tape

90/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
642
Latest evidence
7 Aug 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 126 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 642 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 07 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction48Balanced insider tape
Confidence90Deep evidence
Controlled events489directional common-share events
Company breadth83represented companies
Acquisition value$26.8Mnormalized amount
Disposal value$270.7Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
3420 Jul
8227 Jul
5303 Aug
010 Aug
AcquisitionsDisposalsScore 48 · Confidence 90

Relative positioning

Industry peer map

Current score with confidence.

Pharmaceutical RetailersConviction accumulation7216 confidence Medical DistributionAccumulation bias6667 confidence Drug Manufacturers - GeneralAccumulation bias5794 confidence BiotechnologyBalanced insider tape5291 confidence Medical DevicesBalanced insider tape4890 confidence Diagnostics & ResearchDistribution bias3895 confidence Medical Care FacilitiesDistribution bias3693 confidence Health Information ServicesDistribution bias3691 confidence Medical Instruments & SuppliesDistribution bias3691 confidence Drug Manufacturers - Specialty & GenericDistribution bias3594 confidence Healthcare PlansDistribution bias3492 confidence

Directional balance

Controlled event mix

25.8%acquisition
Acquisition events
126
Disposal events
363
Net value
-$243.9M

Evidence quality

What the filings represent

Common equity1021
Equity compensation301
Options and derivatives231
Other securities10

Decision makers

Role participation

Director886
Other executive252
CEO and chair145
Finance leadership115
Other or unspecified112
Large holder53

Quality controls

Evidence usability

Normalized values
34%
Priced common share
33%
Named insiders
642
Controlled events
489

Auditable evidence

Latest Medical Devices filings

Showing 1291 to 1320 of 1563.

ZBHZimmer Biomet Holdings Inc
HAGEMANN, ROBERTDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
HIGGINS, ARTHUR JDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
HIGGINS, ARTHUR JDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
HILADO, MARIA TERESADirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
HILADO, MARIA TERESADirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
JAFRY, SYED A.Director
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
JAFRY, SYED A.Director
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
KOLLI, SREELAKSHMIDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
KOLLI, SREELAKSHMIDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
KURDIKAR, DEVDATTDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
KURDIKAR, DEVDATTDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
SHAPIRO, LOUISDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
SHAPIRO, LOUISDirector
AcquisitionEquity compensation
Not reportedContext evidence
OFIXOrthofix Medical Inc
JUNIPER, INVESTMENT COMPANY, LLC10% Owner
AcquisitionCommon equity
$2.6MDirectional evidence
DXCMDexCom Inc
COLEMAN, JONEVP, Chief Commercial Officer
DisposalCommon equity
$529.3KDirectional evidence
EWEdwards Lifesciences Corp
CHOPRA, DAVEENCVP, TMTT & Surgical
DisposalCommon equity
$126.9KDirectional evidence
DXCMDexCom Inc
BROWN, MICHAEL JONEVP Chief Legal Compliance Off
DisposalCommon equity
$104.3KDirectional evidence
DXCMDexCom Inc
LEACH, JACOB STEVENDirector, President, CEO, and Director
DisposalCommon equity
$104.3KDirectional evidence
DXCMDexCom Inc
STERN, SADIEEVP Chief People & Culture Off
DisposalCommon equity
$104.3KDirectional evidence
DXCMDexCom Inc
SYLVAIN, JEREME MEVP, Chief Financal Officer
DisposalCommon equity
$104.3KDirectional evidence
ECORElectrocore LLC
LEV, JOSHUA S.CFO and Interim President
DisposalCommon equity
$19.5KDirectional evidence
CLPTClearpoint Neuro Inc
FALLON, LYNNETTE CDirector
AcquisitionEquity compensation
Not reportedContext evidence
CLPTClearpoint Neuro Inc
FLETCHER, R JOHNDirector
AcquisitionEquity compensation
Not reportedContext evidence
CLPTClearpoint Neuro Inc
JOHNSON, B KRISTINEDirector
AcquisitionEquity compensation
Not reportedContext evidence
CLPTClearpoint Neuro Inc
KLEIN, MATTHEW B.Director
AcquisitionEquity compensation
Not reportedContext evidence
CLPTClearpoint Neuro Inc
LIAU, LINDA M.Director
AcquisitionEquity compensation
Not reportedContext evidence
CLPTClearpoint Neuro Inc
RICHARDS, TIMOTHY T.Director
AcquisitionEquity compensation
Not reportedContext evidence
RPIDRapid Micro Biosystems Inc
BIKA, DAFNIDirector
AcquisitionCommon equity
Not reportedContext evidence
RPIDRapid Micro Biosystems Inc
BIKA, DAFNIDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
RPIDRapid Micro Biosystems Inc
KOLLENDER, RICHARD SDirector
AcquisitionOptions and derivatives
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context